These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32780215)

  • 41. P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack.
    Li ZX; Xiong Y; Gu HQ; Fisher M; Xian Y; Johnston SC; Wang YJ
    Stroke; 2021 Jul; 52(7):2250-2257. PubMed ID: 34039032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation.
    Chen H; Power D; Giustino G
    Expert Rev Cardiovasc Ther; 2018 Oct; 16(10):735-748. PubMed ID: 30221557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis.
    Nicolas J; Dangas G; Chiarito M; Pivato CA; Spirito A; Cao D; Giustino G; Beerkens F; Camaj A; Vogel B; Sartori S; Yamamoto K; Kimura T; Kim BK; Baber U; Mehran R
    Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):240-250. PubMed ID: 36564015
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry.
    Moalem K; Baber U; Chandrasekhar J; Claessen BE; Sartori S; Aquino M; Dangas G; Iakovou I; Colombo A; Kini A; Gibson M; Krucoff M; Chieffo A; Moliterno D; Witzenbichler B; Pocock S; Mehran R
    Clin Res Cardiol; 2019 Jun; 108(6):643-650. PubMed ID: 30607496
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Perioperative management of dual anti-platelet therapy.
    Webster TD; Vaishnava P; Eagle KA
    Hosp Pract (1995); 2016 Dec; 44(5):237-241. PubMed ID: 27846735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials.
    Navarese EP; Andreotti F; Schulze V; Kołodziejczak M; Buffon A; Brouwer M; Costa F; Kowalewski M; Parati G; Lip GY; Kelm M; Valgimigli M
    BMJ; 2015 Apr; 350():h1618. PubMed ID: 25883067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. P2Y
    Jin Y; Huang H; Shu X; Chen S; Lu L; Gao X; Wu Z
    Thromb Res; 2021 Feb; 198():115-121. PubMed ID: 33316640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
    Serruys PW; Takahashi K; Chichareon P; Kogame N; Tomaniak M; Modolo R; Chang CC; Komiyama H; Soliman O; Wykrzykowska JJ; de Winter RJ; Ferrario M; Dominici M; Buszman P; Bolognese L; Tumscitz C; Benit E; Stoll HP; Hamm C; Steg PG; Onuma Y; Jüni P; Windecker S; Vranckx P; Colombo A; Valgimigli M
    Eur Heart J; 2019 Aug; 40(31):2595-2604. PubMed ID: 31397487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Omitting aspirin in PCI patients: Myth or reality?
    Alexopoulos D; Mpahara A; Kassimis G
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):711-724. PubMed ID: 31811419
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
    Piccolo R; Feres F; Abizaid A; Gilard M; Morice MC; Hong MK; Kim HS; Colombo A; Bhatt DL; Palmerini T; Stone GW; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1621-1630. PubMed ID: 28838471
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?
    Christodoulidis G; Baber U; Mehran R
    Curr Opin Cardiol; 2014 Jul; 29(4):301-6. PubMed ID: 24842783
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and efficacy of P2Y
    Galli M; Capodanno D; Andreotti F; Crea F; Angiolillo DJ
    Expert Opin Drug Saf; 2021 Jan; 20(1):9-21. PubMed ID: 33180563
    [No Abstract]   [Full Text] [Related]  

  • 54. Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients.
    Sabouret P; Savage MP; Fischman D; Costa F
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):21-34. PubMed ID: 32394296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention.
    Wang HY; Dou KF; Yin D; Xu B; Zhang D; Gao RL
    Am J Cardiol; 2020 Oct; 133():61-70. PubMed ID: 32811654
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Costa F; van Klaveren D; James S; Heg D; Räber L; Feres F; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Zanchin T; Palmerini T; Wallentin L; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
    Lancet; 2017 Mar; 389(10073):1025-1034. PubMed ID: 28290994
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
    O'Donoghue ML; Murphy SA; Sabatine MS
    Circulation; 2020 Aug; 142(6):538-545. PubMed ID: 32551860
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Meta-Analysis Comparing Aspirin Alone Versus Dual Antiplatelet Therapy for the Prevention of Venous Graft Failure Following Coronary Artery Bypass Surgery.
    Hesterberg K; Rawal A; Khan S; Rashid A; Jones D; Siddiqui T; Khader TA; Nayyar M; Shah R
    Cardiovasc Revasc Med; 2020 Jun; 21(6):792-796. PubMed ID: 31672535
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abbreviated Dual Antiplatelet Therapy Followed by P2Y
    Kumar A; Shariff M; Doshi R; Vaz IP
    Am J Cardiovasc Drugs; 2020 Aug; 20(4):355-361. PubMed ID: 31784888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
    Shah RR; Pillai A; Omar A; Zhao J; Arora V; Kapoor D; Poommipanit P
    Catheter Cardiovasc Interv; 2017 Mar; 89(4):E99-E103. PubMed ID: 27184930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.